Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar pchop123 (79.63) Submitted: 1/4/2013 12:04:25 PM : Underperform Start Price: $1.34 PPHM Score: -59.19

Short sellers are on to something with PPHM

Featured Broker Partners


Advertisement